Migraine headache drug (Relpax) recalled after company finds possible microbial contamination

Excerpt:

Pfizer recalled two lots of migraine drug Relpax after finding those lots “may not meet Pfizer’s in-house microbiological specification for the potential presence” of two kinds of bacteria.

That’s according to the Pfizer-written, FDA-posted recall notice.

The recalled lots are No. AR5407, blister cards with six 40 mg tablets, and No. CD4565, boxes with two six-tablet blister cards. Both have an expiration date of February 2022. They were distributed nationwide to wholesalers, retailers, hospitals and healthcare providers in the 50 states and Puerto Rico in June and July.